GNBT Financials 07/16/2014 09:05:59
Generex Biotechnology Corp.
Period Ending Jul 31, 2013 Jul 31, 2012 Jul 31, 2011 Jul 31, 2010
Total Revenue - 29 292 1,173
Cost of Revenue - 11 156 812
Gross Profit - 18 136 360
Operating Expenses
Research and Development 2,193 4,987 10,250 13,361
Sales, General and Admin. 3,937 5,054 14,419 16,429
Non-Recurring Items - - - -
Other - - - -
Operating Income (6,129) (10,024) (24,533) (29,430)
Income From Continuing Operations
Add'l Income/Expense Items (1,895) 1,126 3,066 4,360
Earnings Before Interest and Tax (8,024) (8,898) (21,467) (25,070)
Interest Expense 530 593 209 210
Earnings Before Tax (8,554) (9,490) (21,676) (25,280)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (8,554) (9,490) (21,676) (25,280)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (8,554) (9,490) (21,676) (25,280)
Preferred Stock and Other Adjustments (1,722) (377) (766) -
Net Income Applicable to Common Shareholders (10,277) (9,867) (22,442) (25,280)